An affiliate of Selagine Inc.
selagineplasma@gmail.com312-526-3725
Selagine Plasma Inc.
Selagine’s signature side-view photograph of a brown eye, with Selagine’s shaded blue background and flowing blue waves

RESTORATIVE OCULAR BIOLOGICS

Plasma science,
designed for the eye.

Selagine Plasma is developing qPlasma—a pooled, specification-driven plasma eye drop designed to deliver consistent trophic and immunologic support to the ocular surface.

Explore qPlasma ↘ Partner with us

qPlasma is an investigational product and is not approved for commercial use.

PLASMA SCIENCEOCULAR SURFACE HEALTHTRANSLATIONAL RESEARCH

THE OPPORTUNITY

Moving beyond variable, individually prepared blood-derived eye drops.

Patient-specific serum tears can vary from donor to donor and preparation to preparation. Selagine Plasma is applying pharmaceutical development principles to create a pooled ocular biologic with defined composition, functional potency, and release specifications.

THE qPLASMA PLATFORM

Restorative immunotherapy for the ocular surface.

qPlasma is designed to combine the restorative components of plasma with the immunologic functions of pooled antibodies—while controlling inflammatory exposure through donor selection, pooling, processing, and release testing.

01

Restorative support

Preserves naturally occurring growth factors and proteins that support ocular surface homeostasis.

02

Immunologic function

Uses pooled immunoglobulins and natural anti-cytokine activity to help buffer inflammatory signals.

03

Product consistency

Targets a reproducible composition through large-pool averaging and specification-driven release.

04

Safety by design

Integrates pathogen reduction, nanofiltration, sterile fill-finish, and multi-layer quality testing.

DEVELOPMENT STRATEGY

One controlled path from donor to eye drop.

01

Qualified donors

Selected plasma donors and prespecified donor-pool design.

02

Balanced pooling

Large-pool averaging to reduce biologic variability.

03

Pathogen reduction

Process controls designed to support product safety.

04

Purification

Adsorption and nanofiltration within a controlled process.

05

Ophthalmic fill

Preservative-free, sterile unit-dose presentation.

06

Release testing

Composition, function, safety, and stability testing.

BUILT ON TRANSLATIONAL SCIENCE

An affiliate of Selagine Inc., created to advance plasma-derived ophthalmic therapeutics.

Selagine Plasma brings together ocular surface biology, plasma science, pharmaceutical development, and translational research. The company builds on discoveries originating at the University of Illinois Chicago and a program focused on blood-derived therapies for patients whose needs are not fully met by current dry eye treatments.

Visit Selagine Inc. ↗

LEADERSHIP & ADVISORS

Our team

Experience across ophthalmology, pharmaceutical development, regulatory strategy, and business.

COMPANY UPDATES

News

PRESS RELEASEPR Newswire

Selagine Plasma to Advance Pooled Plasma Eye Drops for Moderate-to-Severe Dry Eye

Selagine Plasma announced receipt of certain intellectual property rights from Selagine Inc. and the University of Illinois Chicago to advance pooled plasma products for ophthalmic use. The program aims to develop a standardized pooled plasma eye drop for moderate-to-severe dry eye, using controlled manufacturing and defined release specifications. The product remains investigational.

Read the full announcement

CONTACT US

Let’s move the science forward.

We welcome conversations with plasma, manufacturing, clinical development, and strategic partners.

selagineplasma@gmail.com

Office

2315 W Taylor St, Ste A
Chicago, IL 60612

Laboratory

2201 W Campbell Park Dr
Chicago, IL 60612

Telephone312-526-3725

Fax312-526-3734